A lawsuit was filed by an investor in Geron Corporation (NASDAQ:GERN) shares over alleged wrongdoing by certain directors and NASDAQ:GERN stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 09/30/2015 -- A shareholder in NASDAQ:GERN shares filed a lawsuit against certain Geron directors over alleged wrongdoing that caused damages to the company and its stockholders.
Investors who purchased shares of Geron Corporation (NASDAQ:GERN) prior to March 2014 and currently hold any of those NASDAQ:GERN shares have certain options and should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.
The plaintiff claims that defendants failed to side effects of its sole product, a cancer drug, and shares of Geron Corporation (NASDAQ:GERN) declined from $4.40 to $1.69 when the news came out.
On March 12, 2014, Geron Corporation (NASDAQ: GERN) announced that the company has received verbal notice from the U.S. Food and Drug Administration ("FDA") that its Investigational New Drug "(IND") application for imetelstat has been placed on full clinical hold, affecting all ongoing company-sponsored clinical trial.
On March 14, 2014 a lawsuit was filed against Geron over alleged Securities Laws Violations. the plaintiff claims that between June 16, 2013, and March 11, 2014, Geron Corporation allegedly omitted to disclose material facts showing imetelstat's poor prospects, including that persistent low-grade liver function test (LFT) abnormalities had been observed in the Phase 2 study of imetelstat in essential thrombocythemia (ET) or polycythemia vera (PV) patients and that there was a potential risk of chronic liver injury following long-term exposure to imetelstat.
Those who purchased shares of Geron Corporation have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego